These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38684152)

  • 1. Unstimulated Luteinizing Hormone for Assessment of Suppression during Treatment of Central Precocious Puberty with 6-Month Subcutaneous Leuprolide Acetate: Correlations with Clinical Response.
    Klein KO; Miller BS; Mauras N
    Horm Res Paediatr; 2024 Apr; ():1-10. PubMed ID: 38684152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 3 Trial of a Small-volume Subcutaneous 6-Month Duration Leuprolide Acetate Treatment for Central Precocious Puberty.
    Klein KO; Freire A; Gryngarten MG; Kletter GB; Benson M; Miller BS; Dajani TS; Eugster EA; Mauras N
    J Clin Endocrinol Metab; 2020 Oct; 105(10):e3660-71. PubMed ID: 32738042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Acting Gonadotropin-Releasing Hormone Analogues for Central Precocious Puberty, Including 45-Mg 6-Month Subcutaneous Leuprolide Acetate: Use for Treatment and Treatment Monitoring.
    Silverman LA; Geffner ME; Benson M
    Horm Res Paediatr; 2024 Apr; ():1-8. PubMed ID: 38653206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Accelerated versus slowly progressive forms of puberty in girls with precocious and early puberty. Gonadotropin suppressive effect and final height obtained with two different analogs.
    Lanes R; Soros A; Jakubowicz S
    J Pediatr Endocrinol Metab; 2004 May; 17(5):759-66. PubMed ID: 15237711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Pre-injection Basal Luteinizing Hormone Concentrations are Common in Girls Treated for Central Precocious Puberty.
    Schubert S; Hvelplund AH; Handberg A; Hagstroem S; Leunbach TL
    J Clin Res Pediatr Endocrinol; 2021 Jun; 13(2):204-211. PubMed ID: 33374097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.
    Luo X; Zhang C; Yang Y; Xu X; Cheng X; Wei H; Wang L; Huang F; Shi X; Cabri P
    Adv Ther; 2023 Oct; 40(10):4574-4588. PubMed ID: 37584898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Central nervous system imaging in girls with central precocious puberty: when is necessary?
    Vuralli D; Gonc EN; Alikasifoglu A; Kandemir N; Ozon ZA
    Arch Endocrinol Metab; 2021 May; 64(5):591-596. PubMed ID: 34033300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR; Aceto T; Weber C; Pang S
    J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of bone maturation, growth rate and adult height in children with central precocious puberty treated with depot leuprolide acetate.
    Klein KO; Dragnic S; Soliman AM; Bacher P
    J Pediatr Endocrinol Metab; 2018 Jun; 31(6):655-663. PubMed ID: 29750651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Leuprolide Acetate 6-Month Depot for the Treatment of Central Precocious Puberty: A Phase 3 Study.
    Klein KO; Mauras N; Nayak S; Sunil B; Martinez-Placencia BM; Dragnic S; Ballina M; Zhou Q; Kansra AR
    J Endocr Soc; 2023 Jun; 7(7):bvad071. PubMed ID: 37334213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring treatment of central precocious puberty using basal luteinizing hormone levels and practical considerations for dosing with a 3-month leuprolide acetate formulation.
    Lee PA; Luce M; Bacher P
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1249-1257. PubMed ID: 27740929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 3, Open-Label, Single-Arm Trial of the Efficacy and Safety of Triptorelin 6-Month Formulation in Chinese Children with Central Precocious Puberty.
    Yu X; Cheng X; Wei H; Xu X; Gong C; Li G; Yao H; Zhou L; Zhong Y; Yang Y; Luo F; Zhang Y; Huang F; Shi X; Cabri P; Luo X
    Adv Ther; 2024 Dec; 41(12):4537-4556. PubMed ID: 39412628
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with Depot Leuprolide Acetate in Girls with Idiopathic Precocious Puberty: What Parameter should be Used in Deciding on the Initial Dose?
    Vurallı D; Alikaşifoğlu A; İyigün İ; Canoruç D; Ozon A; Gönç N; Kandemir N
    J Clin Res Pediatr Endocrinol; 2020 Mar; 12(1):37-44. PubMed ID: 31347350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter clinical trial of leuprolide acetate depot (Luphere depot 3.75 mg) for efficacy and safety in girls with central precocious puberty.
    Kim YJ; Lee HS; Lee YJ; Lim JS; Kim SY; Kim EY; Jin DK; Hwang IT; Hwang JS
    Ann Pediatr Endocrinol Metab; 2013 Dec; 18(4):173-8. PubMed ID: 24904873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triptorelin stimulated luteinizing hormone concentrations for diagnosing central precocious puberty: study of diagnostic accuracy.
    Vukovic R; Milenkovic T; Soldatovic I; Pekic S; Mitrovic K; Todorovic S
    Endocrine; 2022 Mar; 75(3):934-941. PubMed ID: 34826116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of leuprolide acetate response patterns in the early diagnosis of pubertal disorders: comparison with the gonadotropin-releasing hormone test.
    Ibáñez L; Potau N; Zampolli M; Virdis R; Gussinyé M; Carrascosa A; Saenger P; Vicens-Calvet E
    J Clin Endocrinol Metab; 1994 Jan; 78(1):30-5. PubMed ID: 7507123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A single luteinizing hormone determination 2 hours after depot leuprolide is useful for therapy monitoring of gonadotropin-dependent precocious puberty in girls.
    Brito VN; Latronico AC; Arnhold IJ; Mendonca BB
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4338-42. PubMed ID: 15356030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
    Kunz GJ; Sherman TI; Klein KO
    J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1189-98. PubMed ID: 18183790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.